Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab-Reference-Cited by-同舟云学术

Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab

Published:2017-08 Issue:8 Volume:28 Page:2040-2041
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Curioni-Fontecedro A.,Ickenberg C.,Franzen D.,Rogler G.,Burger I.A.,van den Broek M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/8/2040/19388859/mdx233.pdf

Reference5 articles.

1. T cell metabolism drives immunity;Buck;J Exp Med,2015

2. Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with Nivolumab – including histological analysis of one case after tumor regression;Tanizaki;Lung Cancer,2016

3. Characterization of patients treated with a programmed cell death protein 1 inhibitor (anti-PD-1) past RECIST progression from a metastatic non-small cell lung cancer (mNSCLC) trial;Blumenthal;J Clin Oncol,2016

4. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

5. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians;Frontiers in Immunology;2023-03-01

2. FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients;Seminars in Nuclear Medicine;2022-11

3. Pseudoprogression in lung cancer patients treated with immunotherapy;Critical Reviews in Oncology/Hematology;2022-01

4. Patient Selection for Local Aggressive Treatment in Oligometastatic Non-Small Cell Lung Cancer;Cancers;2021-12-19

5. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer;Nature Communications;2021-08-19